Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Non-Viral TCR Gene Therapy

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Endocrine/Neuroendocrine
Gastrointestinal/Genitourinary Cancers
Ovarian Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Aldesleukin
Biological: Sleeping Beauty Transposed PBL

First Posted Date: 2019-09-25

Last Posted Date: 2024-03-12

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04102436

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: ALLO-715
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Nirogacestat

First Posted Date: 2019-09-18

Last Posted Date: 2023-08-14

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 132

Registration Number: NCT04093596

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 8 locations

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric
B Cell Lymphoma
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Autologous CD22 CAR T

First Posted Date: 2019-09-13

Last Posted Date: 2024-02-12

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT04088864

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: B-ALL
DLBCL
Follicular Lymphoma Grade 3B
B-cell Non Hodgkin Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: CD22 CAR

First Posted Date: 2019-09-13

Last Posted Date: 2024-07-25

Lead Sponsor: Stanford University

Target Recruit Count: 52

Registration Number: NCT04088890

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Phase 1

Suspended

Conditions: Non-Malignant Neoplasm

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Lapine T-Lymphocyte Immune Globulin
Radiation: Total-Body Irradiation
Procedure: Hematopoietic Cell Transplantation
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2019-09-10

Last Posted Date: 2024-12-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04083183

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Biological: ATLCAR.CD30 T cells
Drug: Bendamustine
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-09-10

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04083495

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2019-09-10

Last Posted Date: 2024-02-28

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 13

Registration Number: NCT04083963

Locations: 🇺🇸
University of Illinois, Chicago, Illinois, United States

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Phase 2

Terminated

Conditions: Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Acute Erythroid Leukemia
Myelodysplastic Syndrome With Excess Blasts
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation
Biological: Dilanubicel

First Posted Date: 2019-09-10

Last Posted Date: 2025-01-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04083170

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Cleveland Cord Blood Center, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Phase 1

Completed

Conditions: HER2/Neu Negative
Progesterone Receptor Negative
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Anatomic Stage IIA Breast Cancer AJCC v8

Interventions: Drug: Celecoxib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Paclitaxel
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-09-09

Last Posted Date: 2023-09-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT04081389

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1

Active, not recruiting

Conditions: Recurrent Anaplastic Large Cell Lymphoma
Recurrent Mycosis Fungoides
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Anaplastic Large Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Genetically Engineered Lymphocyte Therapy

First Posted Date: 2019-08-30

Last Posted Date: 2024-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04074746

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy